Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (ETNA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01822314 |
Recruitment Status :
Completed
First Posted : April 2, 2013
Last Update Posted : March 7, 2024
|
Sponsor:
Fondazione Michelangelo
Information provided by (Responsible Party):
Fondazione Michelangelo
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 2016 |
Actual Study Completion Date : | March 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):